Cellebrite DI (NASDAQ:CLBT) Sees Strong Trading Volume – Here’s What Happened

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) saw an uptick in trading volume on Monday . 3,496,200 shares changed hands during mid-day trading, an increase of 100% from the previous session’s volume of 1,752,250 shares.The stock last traded at $13.1280 and had previously closed at $12.95.

Analyst Ratings Changes

Several brokerages recently issued reports on CLBT. Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Finally, Needham & Company LLC cut their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Cellebrite DI Stock Performance

The firm has a market cap of $3.46 billion, a P/E ratio of 44.71, a P/E/G ratio of 2.03 and a beta of 1.30. The firm’s fifty day simple moving average is $14.39 and its 200 day simple moving average is $16.69.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.14. The firm had revenue of $128.82 million for the quarter, compared to analysts’ expectations of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The business’s revenue was up 28.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.10 earnings per share. On average, equities research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Institutional Trading of Cellebrite DI

Several hedge funds have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC lifted its position in Cellebrite DI by 40.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 359,764 shares of the company’s stock valued at $6,652,000 after purchasing an additional 103,568 shares during the last quarter. Norwood Investment Partners LP purchased a new position in shares of Cellebrite DI in the 3rd quarter worth $4,274,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Cellebrite DI in the 3rd quarter worth about $19,457,000. Moody National Bank Trust Division purchased a new stake in shares of Cellebrite DI during the 3rd quarter valued at about $2,670,000. Finally, TimesSquare Capital Management LLC purchased a new stake in shares of Cellebrite DI during the 3rd quarter valued at about $11,217,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.